Novel Nuclear Medicine Imaging Applications in Immuno-Oncology.
immune checkpoint inhibitors
immunotherapy
nuclear medicine
positron-emission tomography
single-photon emission computed tomography
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
21 May 2020
21 May 2020
Historique:
received:
19
04
2020
revised:
11
05
2020
accepted:
19
05
2020
entrez:
28
5
2020
pubmed:
28
5
2020
medline:
28
5
2020
Statut:
epublish
Résumé
The global immuno-oncology pipeline has grown progressively in recent years, leading cancer immunotherapy to become one of the main issues of the healthcare industry. Despite their success in the treatment of several malignancies, immune checkpoint inhibitors (ICIs) perform poorly in others. Again, ICIs action depends on such a multitude of clinico-pathological features, that the attempt to predict responders/long-responders with ad-hoc built immunograms revealed to be quite complex. In this landscape, the role of nuclear medicine might be crucial, with first interesting evidences coming from small case series and pre-clinical studies. Positron-emission tomography (PET) techniques provide functional information having a predictive and/or prognostic value in patients treated with ICIs or adoptive T-cell therapy. Recently, a characterization of the tumor immune microenvironment (TiME) pattern itself has been shown to be feasible through the use of different radioactive tracers or image algorithms, thus adding knowledge about tumor heterogeneity. Finally, nuclear medicine exams permit an early detection of immune-related adverse events (irAEs), with on-going clinical trials investigating their correlation with patients' outcome. This review depicts the recent advances in molecular imaging both in terms of non-invasive diagnosis of TiME properties and benefit prediction from immunotherapeutic agents.
Identifiants
pubmed: 32455666
pii: cancers12051303
doi: 10.3390/cancers12051303
pmc: PMC7281332
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
J Immunol. 2014 Jun 15;192(12):5451-8
pubmed: 24907378
N Engl J Med. 2018 Jun 14;378(24):2288-2301
pubmed: 29863955
Mol Imaging. 2019 Jan-Dec;18:1536012119829986
pubmed: 31044647
Cancer Immunol Res. 2018 Jun;6(6):630-635
pubmed: 29622582
J Clin Oncol. 2015 Nov 1;33(31):3541-3
pubmed: 26261262
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
Eur J Cancer. 2015 Nov;51(17):2501-7
pubmed: 26338195
N Engl J Med. 2018 Nov 29;379(22):2108-2121
pubmed: 30345906
Nat Rev Drug Discov. 2019 Mar;18(3):219-234
pubmed: 30679806
Eur J Cancer. 1999 Dec;35(13):1773-82
pubmed: 10673991
Cancer. 1981 Jan 1;47(1):207-14
pubmed: 7459811
Cancer Res. 2016 Jan 1;76(1):73-82
pubmed: 26573799
Lancet Oncol. 2016 Sep;17(9):1283-94
pubmed: 27451390
J Clin Oncol. 2018 Mar 20;36(9):850-858
pubmed: 29341833
Lancet. 2019 May 4;393(10183):1776-1778
pubmed: 30955976
Nat Rev Clin Oncol. 2019 Jun;16(6):341-355
pubmed: 30718843
J Exp Med. 2017 Aug 7;214(8):2243-2255
pubmed: 28666979
Lancet. 2016 May 7;387(10031):1909-20
pubmed: 26952546
J Clin Oncol. 2016 Sep 10;34(26):3119-25
pubmed: 27269937
Lancet. 2017 Jun 24;389(10088):2492-2502
pubmed: 28434648
Lancet. 2018 Feb 24;391(10122):748-757
pubmed: 29268948
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
Curr Opin Oncol. 2014 Mar;26(2):237-44
pubmed: 24441505
J Nucl Med. 2018 Sep;59(9):1423-1429
pubmed: 29626120
Lancet Respir Med. 2019 May;7(5):387-401
pubmed: 30922878
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Lancet Oncol. 2018 Jul;19(7):940-952
pubmed: 29875066
Lancet Oncol. 2017 Mar;18(3):312-322
pubmed: 28131785
J Clin Oncol. 2019 Mar 20;37(9):693-702
pubmed: 30726175
J Nucl Med. 2020 Jan;61(1):117-122
pubmed: 31253743
Mol Cancer. 2017 Feb 16;16(1):41
pubmed: 28209166
Oncotarget. 2018 Jul 13;9(54):30268-30278
pubmed: 30100988
Eur J Nucl Med Mol Imaging. 2017 Aug;44(Suppl 1):55-66
pubmed: 28361188
J Clin Oncol. 2018 Jun 10;36(17):1714-1768
pubmed: 29442540
Lancet Oncol. 2018 Jan;19(1):51-64
pubmed: 29217288
J Immunother Cancer. 2019 Oct 26;7(1):278
pubmed: 31655605
JAMA Oncol. 2019 Apr 1;5(4):546-550
pubmed: 30570649
N Engl J Med. 2015 Jan 22;372(4):320-30
pubmed: 25399552
J Nucl Med. 2019 Sep;60(9):1213-1220
pubmed: 30796165
JAMA Oncol. 2016 Jun 1;2(6):780-1
pubmed: 26913938
N Engl J Med. 2019 Mar 21;380(12):1116-1127
pubmed: 30779529
Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):238-250
pubmed: 30291373
N Engl J Med. 2017 Nov 9;377(19):1824-1835
pubmed: 28891423
PLoS One. 2018 Mar 7;13(3):e0193832
pubmed: 29513764
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Lancet Oncol. 2016 Oct;17(10):1374-1385
pubmed: 27592805
Nat Commun. 2018 Nov 7;9(1):4664
pubmed: 30405135
Nucl Med Commun. 2019 Aug;40(8):802-807
pubmed: 31045745
EJNMMI Res. 2019 Jan 29;9(1):8
pubmed: 30694399
Immunotherapy. 2019 Aug;11(12):1005-1013
pubmed: 31304833
Lancet Oncol. 2017 Nov;18(11):1483-1492
pubmed: 28967485
Clin Cancer Res. 2018 Jun 1;24(11):2653-2664
pubmed: 29530936
J Nucl Med. 2009 May;50 Suppl 1:122S-50S
pubmed: 19403881
Proc (Bayl Univ Med Cent). 2005 Oct;18(4):321-30
pubmed: 16252023
Lancet. 2017 Jan 21;389(10066):255-265
pubmed: 27979383
Cancer Immunol Immunother. 2009 Aug;58(8):1297-306
pubmed: 19139884
Curr Opin Immunol. 2014 Apr;27:16-25
pubmed: 24531241
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
Oncol Lett. 2020 Feb;19(2):1559-1566
pubmed: 31966081
Mol Imaging Biol. 2017 Dec;19(6):903-914
pubmed: 28247187
N Engl J Med. 2016 Nov 10;375(19):1845-1855
pubmed: 27717298
Eur J Nucl Med. 2000;27(1 Suppl):S49-79
pubmed: 10654157
PLoS One. 2020 Feb 25;15(2):e0228793
pubmed: 32097418
Radiology. 2010 Nov;257(2):498-506
pubmed: 20829539
Cancers (Basel). 2019 Aug 31;11(9):
pubmed: 31480470
Ann Transl Med. 2018 Jun;6(11):222
pubmed: 30023385
Clin Nucl Med. 2015 Nov;40(11):e528-9
pubmed: 26284765
J Clin Oncol. 2018 Mar 10;36(8):773-779
pubmed: 29355075
Bioconjug Chem. 2015 Oct 21;26(10):2062-9
pubmed: 26307602
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Clin Nucl Med. 2012 Jun;37(6):629-30
pubmed: 22614208
Oncogene. 2019 Jun;38(25):4887-4901
pubmed: 30816343
PLoS One. 2014 Nov 03;9(11):e109866
pubmed: 25365349
N Engl J Med. 2018 Dec 13;379(24):2342-2350
pubmed: 30280658
N Engl J Med. 2018 May 10;378(19):1789-1801
pubmed: 29658430
Clin Cancer Res. 2007 Feb 1;13(3):972-6
pubmed: 17277252
Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1289-1296
pubmed: 29478079
Oncotarget. 2017 Jun 27;8(26):43536-43542
pubmed: 28402949
Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):376-383
pubmed: 29124281
Eur J Nucl Med Mol Imaging. 2008 Feb;35(2):281-6
pubmed: 17929011
Nat Rev Clin Oncol. 2019 Sep;16(9):563-580
pubmed: 31092901
N Engl J Med. 2019 Oct 17;381(16):1535-1546
pubmed: 31562797
Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):110-120
pubmed: 28821924
J Clin Med. 2019 May 14;8(5):
pubmed: 31091813
J Clin Oncol. 2017 Jul 1;35(19):2125-2132
pubmed: 28441111
Expert Rev Anticancer Ther. 2020 Feb;20(2):137-145
pubmed: 31997676
Clin Cancer Res. 2009 Dec 1;15(23):7412-20
pubmed: 19934295
J Clin Oncol. 2019 Jun 10;37(17):1470-1478
pubmed: 30943124
N Engl J Med. 2019 Mar 21;380(12):1103-1115
pubmed: 30779531
Lancet Oncol. 2017 Mar;18(3):e143-e152
pubmed: 28271869
J Urol. 2008 Jan;179(1):53-6
pubmed: 17997439
Sci Rep. 2018 Jan 8;8(1):105
pubmed: 29311707
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
Cancers (Basel). 2019 Jul 03;11(7):
pubmed: 31277279
Theranostics. 2018 Jul 30;8(15):4199-4209
pubmed: 30128047
Nat Med. 2018 Dec;24(12):1852-1858
pubmed: 30478423
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Q J Nucl Med Mol Imaging. 2007 Dec;51(4):352-6
pubmed: 17923825
Sci Rep. 2020 Jan 20;10(1):643
pubmed: 31959763
N Engl J Med. 2017 Mar 16;376(11):1015-1026
pubmed: 28212060
Lancet Oncol. 2017 Sep;18(9):1182-1191
pubmed: 28734759
Eur J Nucl Med Mol Imaging. 2020 May;47(5):1168-1182
pubmed: 31807885
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
pubmed: 10655437
Ann Oncol. 2018 Oct 1;29(10):2115-2120
pubmed: 30137228
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
Lancet. 2019 Jan 12;393(10167):156-167
pubmed: 30509740
Radiology. 2016 Aug;280(2):576-84
pubmed: 26909647
N Engl J Med. 2018 Dec 6;379(23):2220-2229
pubmed: 30280641
J Nucl Med. 2006 May;47(5):885-95
pubmed: 16644760
J Nucl Med. 2020 Apr 24;:
pubmed: 32332144
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
N Engl J Med. 2015 Jun 25;372(26):2521-32
pubmed: 25891173
Clin Cancer Res. 2013 Jul 15;19(14):3936-43
pubmed: 23743568
Clin Nucl Med. 2019 Nov;44(11):905-906
pubmed: 31584495
J Nucl Med. 2017 Sep;58(9):1421-1428
pubmed: 28360208
Eur J Nucl Med Mol Imaging. 2018 Jun;45(6):1072-1075
pubmed: 29532102
Acad Radiol. 2017 Jan;24(1):111-115
pubmed: 27818005
JAMA Oncol. 2019 Jul 1;5(7):1008-1019
pubmed: 31021376
PLoS One. 2019 May 14;14(5):e0216954
pubmed: 31086392
J Clin Oncol. 2019 Oct 1;37(28):2518-2527
pubmed: 31154919
Eur J Nucl Med Mol Imaging. 2015 Mar;42(3):386-96
pubmed: 25359635
Eur J Cancer. 2018 Jun;96:91-104
pubmed: 29698933
Mol Pharm. 2017 May 1;14(5):1782-1789
pubmed: 28388076
Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):56-66
pubmed: 28828507
Cancer Immunol Immunother. 2019 Feb;68(2):297-303
pubmed: 30478475
Eur J Nucl Med Mol Imaging. 2010 Jan;37(1):181-200
pubmed: 19915839
JAMA Oncol. 2018 May 10;4(5):e180013
pubmed: 29543932
J Natl Cancer Inst. 2012 Apr 18;104(8):590-8
pubmed: 22491345
Nat Rev Cancer. 2019 Mar;19(3):133-150
pubmed: 30755690
Clin Nucl Med. 2019 Apr;44(4):e272-e279
pubmed: 30688730
Immunotherapy. 2019 Jun;11(8):667-676
pubmed: 31088239
J Thorac Oncol. 2018 Aug;13(8):1113-1120
pubmed: 29704674
JAMA Oncol. 2018 Mar 1;4(3):374-378
pubmed: 28975219
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):328-54
pubmed: 25452219
Eur J Nucl Med Mol Imaging. 2018 Feb;45(2):207-217
pubmed: 28944403
Front Oncol. 2018 Sep 25;8:390
pubmed: 30319963
Immunity. 2019 Feb 19;50(2):477-492.e8
pubmed: 30737146
Ann Oncol. 2017 Jul 1;28(suppl_4):iv119-iv142
pubmed: 28881921
Sci Rep. 2018 Jan 12;8(1):633
pubmed: 29330552